The United States Supreme Court has issued a temporary stay to maintain current federal regulations allowing the distribution of mifepristone via mail and telehealth, overturning a recent appellate court restriction.

美國最高法院已發布臨時暫緩執行令，以維持目前允許透過郵寄和遠端醫療分發米非錯構酮的聯邦法規，推翻了近期上訴法院的限制。

The legal dispute originated from a challenge by the state of Louisiana, which asserted that the Food and Drug Administration's (FDA) 2023 decision to eliminate in-person dispensing requirements undermined the state's comprehensive abortion prohibitions. On May 1, the U.S. Court of Appeals for the 5th Circuit ruled in favor of Louisiana, mandating a return to in-person clinic visits for the acquisition of the medication. This appellate decision was predicated on the finding that the FDA failed to sufficiently analyze the safety of remote prescribing and that the state possessed legal standing due to Medicaid expenditures associated with complications arising from the drug's use.

這場法律爭議源於路易斯安那州的挑戰，該州主張食品藥品監督管理局（FDA）於 2023 年決定取消親自領藥要求，削弱了該州全面的墮胎禁令。5 月 1 日，美國第五巡迴上訴法院裁定路易斯安那州勝訴，強制要求獲取該藥物必須恢復親自前往診所。此上訴裁決是基於 FDA 未能充分分析遠端開藥的安全性，且由於該州承擔了與藥物副作用相關的醫療補助（Medicaid）支出，因此具有法律地位。

In response, pharmaceutical manufacturers Danco Laboratories and GenBioPro sought emergency relief from the Supreme Court. Justice Samuel Alito subsequently granted an administrative stay, effective until May 11, which restores the status quo of mail-order and pharmacy access. This intervention prevents the immediate implementation of the 5th Circuit's order, which critics argued would create regulatory instability and impede access for patients in rural or restrictive jurisdictions. The Supreme Court's current posture reflects a tension between the 5th Circuit's interpretation of state standing and the high court's 2024 precedent in FDA v. Alliance for Hippocratic Medicine, which dismissed similar challenges based on a lack of legal standing.

對此，製藥商 Danco Laboratories 和 GenBioPro 向最高法院尋求緊急救濟。隨後，大法官 Samuel Alito 批准了行政暫緩執行令，有效期至 5 月 11 日，恢復了郵寄和藥局獲取藥物的現狀。此干預防止了第五巡迴法院命令的立即執行，批評者認為該命令將造成監管不穩定，並阻礙鄉村或限制較多管轄區患者的獲取途徑。最高法院目前的立場反映了第五巡迴法院對州法律地位的解釋，與最高法院 2024 年在 "FDA 訴 Hippocratic Medicine 聯盟" 案中，因缺乏法律地位而駁回類似挑戰的先例之間的緊張關係。

Beyond the immediate litigation, the situation is complicated by the Trump administration's stated intent to review the drug's approval process. While the FDA has conducted its own safety review of the Risk Evaluation and Mitigation Strategies (REMS), the 5th Circuit declined to await the conclusion of this administrative process. The broader implications for the biotechnology sector involve concerns regarding the potential for judicial override of scientific regulatory frameworks, which may introduce unpredictability into the drug approval and distribution pipeline.

除了目前的訴訟，川普政府表示有意審查該藥物的核准程序，使情況更加複雜。儘管 FDA 已對風險評估與緩解策略（REMS）進行了自身的安全性審查，但第五巡迴法院拒絕等待此行政程序的結果。對生物技術領域而言，更廣泛的影響在於對司法推翻科學監管框架之可能性的擔憂，這可能會為藥物核准與分發流程引入不可預測性。

Mifepristone remains available via telehealth and mail until May 11, pending further deliberation and responses from the state of Louisiana.

在等待路易斯安那州的進一步審議與回應之前，米非錯構酮在 5 月 11 日前仍可透過遠端醫療和郵寄獲取。